The KMT2A recombinome of acute leukemias in 2023Claus Meyer, Emmanuelle Clappier, Nicola C. Venn et al.|Leukemia|2023Cited by 214
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Vindi Jurinović et al.|Hematological Oncology|2025Cited by 1
265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECTSimone Ragaini, Marco Ladetto, Riccardo Moia et al.|Hematological Oncology|2025Cited by 1